Harm Reduction
4 articles on Harm Reduction, researched and written by the Shotlee Editorial Team from primary sources.
Black-Market Peptide Surge Strains Needle and Syringe Programs
The rise of unregulated peptides for performance and image enhancement is placing significant pressure on vital harm reduction services, originally established to combat HIV. These programs are now facing increased demand and potential shortages of essential supplies.
7 min read
Beyond the Hype: Black Market Peptides Strain Vital Health Services
The booming trade in unregulated peptides for weight loss and body enhancement is placing unprecedented pressure on essential harm reduction services, originally established to combat the HIV epidemic. This article delves into the challenges, risks, and urgent needs arising from this new wave of drug use.
7 min read
GLP-1s Reduce Substance Addiction Risk in US Veterans: BMJ Study
An observational study in the British Medical Journal reveals GLP-1 medications like semaglutide significantly lower substance use disorder (SUD) risk in US veterans with type 2 diabetes. Compared to SGLT2 inhibitors, GLP-1s reduced new addiction risks by up to 25% and improved outcomes like 50% fewer substance-related deaths. These findings challenge traditional views on addiction and metabolic health.
5 min read
South Africa's 2026 Agenda Spotlights GLP-1 Obesity Drugs
One-third of South Africans live with obesity, driving new clinical guidelines that endorse GLP-1 drugs like Ozempic, Mounjaro, and Wegovy. These medications lower blood sugar, slow digestion, and promote fullness but face affordability barriers. Experts urge political action for broader access.
4 min read